Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Pediatric Hematology/Oncology and ImmunopathologyOpen Access

Experience in developing and scaling a protocol for NK lymphocyte enriched cellular product manufacturing for clinical application

View Full Paper
Ask AI
Bookmark
Share

Authors

EKE. A. KulakovskayaVBV. E. BelchikovVVVictoria A. Vedmedskaia

Discussion

Loading...

Member takes

Overview

Protocol demonstrates effective NK cell expansion and cytotoxic activity in pediatric leukemia treatment.

Key Points

  • NK lymphocyte expansion protocol achieved desired clinical dosage, demonstrating effective cytotoxic activity.
  • Quality control criteria were met, with high percentage of NK cells and low percentage of residual TCRab+ T cells.
  • Independent Ethics Committee approved the process, confirming safety for pediatric leukemia treatment.
  • The protocol results establish a foundation for clinical study on NK lymphocyte-enriched products.

Cite This Study

Kulakovskaya et al. (2025) studied this question.

synapsesocial.com/papers/68c1955c9b7b07f3a061927chttps://doi.org/10.24287/1726-1708-2025-24-2-27-37
View Full Paper
Ask AI
Bookmark
Share